
AGENDA

Mayflower Renaissance Hotel, 1127 Connecticut Avenue NW

Wednesday, February 29th

3-6:00 pm Registration open.....Promenade outside State Room

6:30 pm Opening Reception.....Chinese Room
Welcome: Debra Black, MRA Co-Founder and Chair of the Board

Thursday, March 1st

6:30-5:00 Registration open.....Promenade outside State Room

7:00-8:00 Breakfast.....East Room

8:00-8:10 Opening Remarks.....State Room
Wendy K.D. Selig, MRA President and Chief Executive Officer

8:10-11:20 Therapeutic drug combinations and resistance mechanisms

Chair: Levi Garraway, Dana-Farber Cancer Institute

8:10-8:35 David Solit, Memorial Sloan-Kettering Cancer Center, Studies on the mechanism(s) of de novo and acquired resistance to RAF inhibition

8:35-8:55 Christine Pratilas, Memorial Sloan-Kettering Cancer Center, Feedback adaptation of RAF-MEK-ERK signaling in BRAF mutant melanomas

8:55-9:20 Leonard Zon, Children's Hospital Boston, Neural crest stem cell programs as targets in melanoma

9:20-9:40 David Dankort, McGill University, Targeting critical Pten/PI3K pathway targets in BrafV600E malignant melanoma

9:40-9:55 BREAK

9:55-10:20 Martin McMahon, University of California, San Francisco, Targeting signaling pathways for therapy in a new mouse model of melanoma

10:20-10:40 Bin Zheng, Columbia University, Targeting the LKB1-AMPK signaling pathway in malignant melanoma

10:40-11:00 Christian Blank, Netherlands Cancer Institute, Development of combined molecular/immunotherapy regimens for human melanoma

11:00-11:25 Levi Garraway, Dana-Farber Cancer Institute, Perspective

11:45-12:50 Lunch.....East Room
Speaker: Congressman Brian Bilbray (R-CA)

Thursday, March 1st (cont.)

- 1:00-2:15 Early melanoma detection and skin screening trials.....State Room**
Chair: Martin Weinstock, Rhode Island Hospital, Brown University,
VA Medical Center
- 1:00-1:25 Martin Weinstock, Rhode Island Hospital, Developing melanoma screening
in primary care
- 1:25-1:50 Allan Halpern, Memorial Sloan-Kettering Cancer Center, Comprehensive
diagnostic imaging system for melanoma detection
- 1:50-2:15 Alexander Katalinic, University of Lübeck, Results of the German skin cancer
screening experience
- 2:15-2:30 *BREAK*
- 2:30-5:00 Melanoma vaccines.....State Room**
Chair: Glenn Dranoff, Dana-Farber Cancer Institute
- 2:30-2:55 Tom Gajewski, University of Chicago, Multi-peptide vaccination with or
without IL-12 and Daclizumab
- 2:55-3:20 Willem Overwijk, MD Anderson Cancer Center, Entrapment and deletion of
melanoma-specific T cells at vaccination sites
- 3:20-3:45 Craig Slingluff, University of Virginia, Combined immunotherapy of
melanoma with long peptides and TLR agonists
- 3:45-4:10 Nina Bhardwaj, New York University, Modulating anti-tumor immunity with
dendritic cells
- 4:10-4:35 T-C Wu, Johns Hopkins University, Treatment of melanoma combining
cancer gene therapy and immunotherapy
- 4:35-5:00 Glenn Dranoff and Kai Wucherpfennig, Dana-Farber Cancer Institute,
The isolation of human anti-MICA monoclonal antibodies
- 5:00 Closing remarks:** Laura Brockway-Lunardi, MRA Scientific
Program Director
- 7:00-9:00 Dinner.....Lincoln Restaurant**
Evening program: Senator John Kerry (D-MA) and
Ed Goas, President and CEO, Tarrance Group
6:45 pm: Transportation to restaurant, Pick up Desales St. entrance of hotel
Address: 1110 Vermont Ave. NW, Ph: 202-386-9200

Friday, March 2nd

- 6:30-10 am *Registration open.....Promenade outside State Room*
- 7:00-8:30 Young Investigators breakfast (by invitation only).....Chinese Room
- 7:00-8:30 General breakfast.....East Room
- 8:30-11:30 Novel biomarkers for staging and therapeutics.....State Room**
Chair: Jeffrey Gershenwald, MD Anderson Cancer Center
- 8:30-8:55 Jeffrey Gershenwald, MD Anderson Cancer Center, Clinicopathologic and
molecular staging and prognosis in early-stage melanoma
- 8:55-9:15 Li Zhou, Henry Ford Health System, Circulating microRNAs as diagnosis and
staging biomarkers for melanoma

Friday, March 2nd (cont.)

9:15-9:35 Raya Leibowitz-Amit, Sheba Medical Center, miRNA down-regulation in melanoma– Diagnostic and therapeutic implications

9:35-9:55 Remco van Doorn, Leiden University Medical Center, Epigenomic analysis of melanoma metastatic behavior

9:55-10:15 *BREAK*

10:15-10:40 Boris Bastian, University of California, San Francisco, Development of targeted therapies for Gq/11 mutant melanomas

10:40-11:05 J. William Harbour, Washington University in St. Louis, Targeting the Bap1 tumor suppressor gene in a mouse model of melanoma

11:05-11:30 Jedd Wolchok, Memorial Sloan-Kettering Cancer Center, Immunologic signatures of response to Ipilimumab

11:30-12:30 Panel discussion: Development of melanoma biomarkers for diagnostics and standard-of-care

Co-chairs: Lynda Chin, MD Anderson Cancer Center and Gideon Bollag, Plexxikon, Inc.

Panelists:

- Barbara Conley, National Cancer Institute
- Patricia Keegan, U.S. Food and Drug Administration
- Kiran Patel, GlaxoSmithKline
- Steve Usdin, BioCentury
- Jedd Wolchok, Memorial Sloan-Kettering Cancer Center

12:30 Closing remarks: Suzanne Topalian, MRA Chief Science Officer

12:30-1:30 Lunch.....East Room